, Tracking Stock Market Picks
Enter Symbol:
Repros Therapeutics Inc. (RPRX) [hlAlert]

down 54.71 %

Repros Therapeutics Inc. (RPRX) rated Overweight by Piper Jaffray

Posted on: Wednesday,  Nov 27, 2013  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight Repros Therapeutics Inc. (NASDAQ: RPRX) on 11/27/2013, when the stock price was $15.90. Since
then, Repros Therapeutics Inc. has lost 54.72% as of 01/14/2016's recent price of $7.20.
If you would have followed this Piper Jaffray's recommendation on RPRX, you would have lost 54.71% of your investment in 778 days.

Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. The second product candidate, Androxal, is a single isomer of clomiphene citrate and an orally active small molecule compound.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/27/2013 8:25 AM Buy
as of 12/13/2013
1 Week up  0.82 %
1 Month up  8.05 %
3 Months   
1 YTD up  8.05 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy